165 related articles for article (PubMed ID: 37515826)
1. Exploring mental health comorbidities and opioid agonist treatment coverage among people in prison: A national cohort study 2010-2019.
Bukten A; Skjærvø I; Stavseth MR
Drug Alcohol Depend; 2023 Sep; 250():110896. PubMed ID: 37515826
[TBL] [Abstract][Full Text] [Related]
2. Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.
Rolová G; Skurtveit S; Gabrhelík R; Mravčík V; Odsbu I
Addict Sci Clin Pract; 2024 May; 19(1):37. PubMed ID: 38741162
[TBL] [Abstract][Full Text] [Related]
3. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
4. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia.
Bazazi AR; Culbert GJ; Wegman MP; Heimer R; Kamarulzaman A; Altice FL
BMC Infect Dis; 2022 Nov; 22(1):837. PubMed ID: 36368939
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
[TBL] [Abstract][Full Text] [Related]
6. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
7. Opioid agonist therapy and mortality among First Nations and other residents with concurrent alcohol use disorder in British Columbia, Canada: A population-based cohort study.
Barker B; Min JE; Homayra F; Piske M; Sabeti S; Meilleur L; Nosyk B; Wieman N
Drug Alcohol Depend; 2023 Sep; 250():110908. PubMed ID: 37544037
[TBL] [Abstract][Full Text] [Related]
8. Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020.
Durand L; Keenan E; O'Reilly D; Bennett K; O'Hara A; Cousins G
BMC Psychiatry; 2023 Oct; 23(1):725. PubMed ID: 37803285
[TBL] [Abstract][Full Text] [Related]
9. Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study.
Palis H; Zhao B; Young P; Korchinski M; Greiner L; Nicholls T; Slaunwhite A
Subst Abuse Treat Prev Policy; 2022 Nov; 17(1):77. PubMed ID: 36434706
[TBL] [Abstract][Full Text] [Related]
10. Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study.
Curtis M; Wilkinson AL; Dietze P; Stewart AC; Kinner SA; Winter RJ; Aitken C; Walker SJ; Cossar RD; Butler T; Stoové M
Harm Reduct J; 2023 Mar; 20(1):42. PubMed ID: 36978089
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.
Morozova O; Crawford FW; Cohen T; Paltiel AD; Altice FL
Addiction; 2020 Mar; 115(3):437-450. PubMed ID: 31478285
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
13. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
14. Posttraumatic stress disorder in opioid agonist therapy: A review.
Ecker AH; Hundt N
Psychol Trauma; 2018 Nov; 10(6):636-642. PubMed ID: 28758767
[TBL] [Abstract][Full Text] [Related]
15. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
[TBL] [Abstract][Full Text] [Related]
16. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and comorbidity of mental health and substance use disorders in Scandinavian prisons 2010-2019: a multi-national register study.
Bukten A; Virtanen S; Hesse M; Chang Z; Kvamme TL; Thylstrup B; Tverborgvik T; Skjærvø I; Stavseth MR
BMC Psychiatry; 2024 Feb; 24(1):95. PubMed ID: 38317111
[TBL] [Abstract][Full Text] [Related]
18. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV.
Wyse JJ; Robbins JL; McGinnis KA; Edelman EJ; Gordon AJ; Manhapra A; Fiellin DA; Moore BA; Korthuis PT; Gaither JR; Gordon K; Skanderson M; Barry DT; Crystal S; Justice A; Kraemer KL
Drug Alcohol Depend; 2019 May; 198():70-75. PubMed ID: 30878769
[TBL] [Abstract][Full Text] [Related]
19. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
20. Informing youth-centred opioid agonist treatment: Findings from a retrospective chart review of youths' characteristics and patterns of opioid agonist treatment engagement in a novel integrated youth services program.
McInerney K; Marchand K; Buckley J; Gao C; Kestler A; Mathias S; Argyle A; Barbic S
Early Interv Psychiatry; 2023 Oct; 17(10):1028-1037. PubMed ID: 37259685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
